146 related articles for article (PubMed ID: 3299819)
1. A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon.
van der Meer J; Wouda AA; Kallenberg CG; Wesseling H
Vasa Suppl; 1987; 18():71-5. PubMed ID: 3299819
[No Abstract] [Full Text] [Related]
2. Treatment of claudication with dipyridamole and aspirin.
Libretti A; Catalano M
Int J Clin Pharmacol Res; 1986; 6(1):59-60. PubMed ID: 3514494
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
4. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
Rhedda A; McCans J; Willan AR; Ford PM
J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
[TBL] [Abstract][Full Text] [Related]
5. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
[No Abstract] [Full Text] [Related]
6. [Nicardipine in the treatment of Raynaud's phenomenon].
Kahan A; Amor B; Menkès CJ
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
[TBL] [Abstract][Full Text] [Related]
7. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
[TBL] [Abstract][Full Text] [Related]
8. Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial.
Rajah SM; Salter MC; Donaldson DR; Subba Rao R; Boyle RM; Partridge JB; Watson DA
J Thorac Cardiovasc Surg; 1985 Sep; 90(3):373-7. PubMed ID: 3897722
[TBL] [Abstract][Full Text] [Related]
9. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Forbes CD
Int J Clin Pract; 1997 Jun; 51(4):205-8. PubMed ID: 9287258
[TBL] [Abstract][Full Text] [Related]
10. [Controlled clinical trial of the effect of aspirin and aspirin + dipyridamole on the development of diabetic retinopathy. I. General protocol. From the DAMAD Study Group (author's transl)].
Diabete Metab; 1982 Jun; 8(2):91-6. PubMed ID: 7049782
[TBL] [Abstract][Full Text] [Related]
11. A randomized double blind comparison of an aspirin dipyridamole combination versus a placebo in the treatment of necrobiosis lipoidica.
Statham B; Finlay AY; Marks R
Acta Derm Venereol; 1981; 61(3):270-1. PubMed ID: 6167117
[TBL] [Abstract][Full Text] [Related]
12. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
[TBL] [Abstract][Full Text] [Related]
13. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
14. [Dipyridamole plus acetylsalicylic acid--who is to be trusted?].
Almdal TP; Eldrup E; Godtfredsen J; Kofoed-Enevoldsen A
Ugeskr Laeger; 1999 Aug; 161(34):4771-2. PubMed ID: 10500471
[No Abstract] [Full Text] [Related]
15. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
17. [The effect of nifedipine (Adalat) on Raynaud's phenomenon].
Baadsgaard O; Schmidt JF; Ironmann L
Ugeskr Laeger; 1983 Dec; 145(49):3814-6. PubMed ID: 6364517
[No Abstract] [Full Text] [Related]
18. [A double-blind clinical trial of a topical preparation with a base of biochemical precursors of glucosaminoglycan (GAG) in patients suffering from Raynaud's disease].
Signorini GP
Boll Chim Farm; 1986 Oct; 125(10):103S-110S. PubMed ID: 3551995
[No Abstract] [Full Text] [Related]
19. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
20. [Use of nifedipine in patients with Raynaud's phenomenon].
Rozwodowska M; Polaszewska-Muszyńska M; Ukleja-Adamowicz M; Rewakowicz M; Guzowska M; Marunowska A; Jundziłł W; Wodyńska T; Ruchalski M; Strzelecki A
Kardiol Pol; 1987; 30 Suppl():97-105. PubMed ID: 3331405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
